GlobalData on MSN1d
Novartis and Olema expand alliance with $250m to boost breast cancer trialsOlema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s ...
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be ...
Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and ...
Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been given an average rating of “Buy” by the six brokerages that are covering the company, Marketbeat reports.
Olema Pharmaceuticals prepares for its OPERA-02 study, targeting ER+/HER2- breast cancer. Read why OLMA stock could benefit ...
A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy. Olema will hold a conference call to discuss these ...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report)’s share price gapped up prior to trading on Friday .The stock had previously closed at $7.87, but opened at $8.21. Olema ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback